In this study, we combined functional analysis of short-term melanoma cell models with high dimensional flow cytometric profiling of matched tumor samples from melanoma patients progressing on PD1 inhibitor monotherapy or in combination with the CTLA4 inhibitor, ipilimumab. This evidence concerns the gene CTLA4 and neoplasm.